Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.51 |
| ▸ | LIPE | Q05469 | 6/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389470 | 0.94 | RXRA (0.53) | RXRANR1H2NR1H3LIPEIDO1 | |
| SCHEMBL4901898 | 0.88 | NR1H2 (0.52) | RXRANR1H2NR1H3MGAT2P2RX3 | |
| SCHEMBL2385120 | 0.85 | NR1H2 (0.54) | RXRANR1H2NR1H3ALDH1A1GLA | |
| SCHEMBL2266726 | 0.84 | NR1H2 (0.65) | RXRANR1H2NR1H3ALDH1A1GLA | |
| SCHEMBL2264600 | 0.84 | NR1H2 (0.60) | RXRANR1H2NR1H3ALDH1A1GLA | |
| SCHEMBL2387415 | 0.82 | NR1H2 (0.59) | RXRANR1H2NR1H3SCN9AMGAT2 | |
| SCHEMBL12390653 | 0.82 | NR1H2 (0.60) | RXRANR1H2NR1H3ALDH1A1GLA | |
| SCHEMBL2391099 | 0.82 | NR1H2 (0.60) | RXRANR1H2NR1H3ALDH1A1GLA | |
| SCHEMBL2262290 | 0.82 | NR1H2 (0.62) | RXRANR1H2NR1H3SCN9AALDH1A1 | |
| SCHEMBL2262577 | 0.82 | NR1H2 (0.62) | RXRANR1H2NR1H3ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.